What is the current stock price of Pliant Therapeutics, Inc. (PLRX)?

As of the latest market data, Pliant Therapeutics, Inc. (PLRX) is trading at $1.28. The stock has seen a loss of -5.19% today.

Does Pliant Therapeutics, Inc. (PLRX) pay a dividend?

Based on current data, Pliant Therapeutics, Inc. does not have a confirmed active dividend policy.

What is the market cap of Pliant Therapeutics, Inc.?

The current market capitalization of Pliant Therapeutics, Inc. (PLRX) is approximately unavailable.

PLRX

Pliant Therapeutics, Inc.·Healthcare

1.28

5.185%(−0.07)

Market Closed

1.48

15.625%(+0.20)

After Hours

Last Updated: — ET

52W L: $1.0952W H: $1.95

PLRX NEWS

defenseworld.net

Mar 21

Head-To-Head Review: Pliant Therapeutics (NASDAQ:PLRX) versus Dermata Therapeutics (NASDAQ:DRMA)

Dermata Therapeutics (NASDAQ: DRMA - Get Free Report) and Pliant Therapeutics (NASDAQ: PLRX - Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, dividends, analyst recommendations and profitability. Profitability This table compares Dermata Therapeutics and

globenewswire.com

Mar 18

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced the presentation of data from the Phase 1 trial of PLN-101095 at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California from April 17-22, 2026.

globenewswire.com

Mar 11

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

PLN-101095 Phase 1 data showed deep and durable ongoing responses in checkpoint inhibitor refractory solid tumors PLN-101095 accelerated development plan underway with initiation of Phase 1b indication expansion trial SOUTH SAN FRANCISCO, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today provided a corporate update and reported fourth quarter 2025 financial results.

seekingalpha.com

Mar 6

Stock Picks From Seeking Alpha's February 2026 New Analysts

In February, we welcomed 17 new analysts to Seeking Alpha. This article showcases their stock picks and investment strategies. Analysts offered qualified investment opinions with detailed justifications based on market trends, company fundamentals, and sector-specific challenges. Key investment theses include bullish views on SFL, SoFi, Bumble, and Pagaya Corporation.

seekingalpha.com

Feb 24

Pliant Therapeutics: A Reverse Arbitrage Opportunity Driven By A Poison Pill Expiration

Pliant Therapeutics trades at a deep discount to net cash after Bexotegrast's Phase 3 failure, with a $70M market cap versus $186M cash. Activist Kevin Tang holds 9.6%; given the 85%+ institutional base, the March 2026 poison pill expiration signals a potential liquidation or premium buyout. PLRX's cash burn has been slashed, extending runway to 2028, but continued independent operation is untenable; forced liquidation or cash privatization is highly likely in my opinion.

globenewswire.com

Feb 23

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical-stage biotechnology company focused on the discovery and development of integrin-based therapeutics, today announced its participation in the Oppenheimer 36th Annual Healthcare Life Sciences Conference being held in a virtual format February 25-26, 2026.

Company Profile

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Sector

Healthcare

Industry

Biotechnology

Employees

171

IPO Date

2020-06-03

Beta

1.25

Websitepliantrx.com↗